Mounjaro (tirzepatide) explained — how it works, who it's for, and what to expect

What tirzepatide actually is

Tirzepatide is a once-weekly injectable peptide medicine. Chemically, it's a single molecule designed to bind to two different gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones are involved in how the body manages hunger, satiety, blood sugar, and how quickly the stomach empties after eating. Tirzepatide essentially turns the volume up on these signals long after a meal has finished, in a way the body's own short-lived hormones don't.

That dual-agonist design is what separates it from the GLP-1-only family of medicines, including semaglutide (Wegovy/Ozempic) and liraglutide (Saxenda). The added GIP activity appears to amplify weight reduction and may also blunt some of the side effects driven by GLP-1 alone — although it doesn't eliminate them.

Who the UK licence is for

The MHRA licence for Mounjaro in weight management covers adults with a BMI of 30 or more, or 27–30 with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease). For NHS access via NICE TA1026, the thresholds are tighter: BMI ≥35 (≥32.5 in some ethnic groups, including South Asian, Chinese, Black African, and African-Caribbean) with at least one comorbidity, delivered through specialist weight management services.

Private prescribing follows the MHRA licence, but a responsible prescriber will only initiate treatment after a full consultation that confirms BMI, comorbidities, contraindications, and that you've had genuine prior efforts at lifestyle change.

The dose escalation

Tirzepatide is escalated slowly to give the gut time to adapt. The standard schedule starts at 2.5 mg once weekly for the first 4 weeks, then steps up to 5 mg, with further increases (7.5, 10, 12.5, 15 mg) at intervals of at least 4 weeks depending on tolerability and clinical response.

The lowest dose is a starter dose only — it's not a maintenance dose. Most people stay on 5–15 mg for ongoing weight management, with the dose tailored to side effects and response. This stepwise approach is one reason rushing escalation tends to backfire: faster escalation usually means worse nausea, which usually means people stop early and don't get the benefit.

The first month, honestly

The first injection is almost always anticlimactic. People expect to feel something straight away — they rarely do. What changes over the first 7–14 days is appetite. The signal most people describe is that they simply don't think about food as much. Portions feel adequate sooner. Snacking becomes effortful rather than automatic. By weeks 3–4, weight on the scale starts to move.

Side effects in the first month are usually mild to moderate: some nausea (especially after larger or fattier meals), mild constipation, occasional fatigue, and sometimes a metallic taste. These tend to settle as the body adapts. The strongest single piece of advice from clinical experience: eat smaller portions, eat slowly, and don't push through a meal when you feel full. The medication is telling you to stop — listen to it.

What the structured programme means in 2026

Following MHRA action on prescribing standards, every UK Mounjaro prescription now sits inside a structured weight management programme. That means the prescription isn't the service — it's one component. A compliant programme includes a clinical consultation before initiation, dietary and behavioural support, monitoring during escalation, side effect management, and a plan for what happens at maintenance and on discontinuation.

Pharmacist-led services are well-suited to this because the model already centres on accessible, continuous care: you can drop in for a consult, talk through how you're feeling on a dose, and adjust the plan in real time rather than waiting weeks for a remote review.

Side effects to know about

The common, expected side effects (nausea, mild constipation, reduced appetite, mild fatigue, occasional reflux) are usually manageable with portion control, hydration, and time. They tend to peak after each dose increase and settle within 1–2 weeks.

The serious side effects are rare but worth knowing about. Pancreatitis presents as severe, persistent upper abdominal pain, often radiating to the back; it's a stop-medication-and-seek-care situation. Gallbladder problems (sometimes triggered by rapid weight loss in general, not just by tirzepatide) can cause right-upper-quadrant pain. Severe dehydration is a risk if vomiting is significant. And like all GLP-1-family medicines, tirzepatide carries a precaution around personal or family history of medullary thyroid cancer or MEN2 — these are contraindications.

Cost, plainly

We don't list prices in this guide because they change and they vary by dose, supply chain, and what's included in a programme. What we will say is that a responsible private price should bundle in the consultation, ongoing monitoring, dietary support, and side-effect access to a clinician — not just the pen on its own. If a service is selling pens with no wraparound, that's not a programme; it's a sales channel.

The 'rebound' question

This comes up in every consultation. Tirzepatide is for chronic weight management — meaning, on the licence and on the evidence, it works while you take it. When people stop, the appetite-suppression effect fades over weeks to months and weight typically returns over 12–24 months unless the underlying habits have changed.

The honest framing is this: the medication gives you a window — usually 12–18 months of strong appetite control — to rebuild eating patterns, physical activity, and lifestyle scaffolding so that, when you taper or stop, the new habits hold. The medication does not, on its own, change behaviour permanently. That's why ongoing pharmacist and dietary support matter at maintenance, not just during the loss phase.

When not to use it

Tirzepatide isn't appropriate for everyone. Absolute contraindications include personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and known hypersensitivity to the active ingredient. Cautions and shared-decision conversations apply if you have a history of pancreatitis, severe gastrointestinal disease (including gastroparesis), severe renal impairment, are pregnant or planning pregnancy, or breastfeeding.

If you're under 18, currently on insulin, or have type 1 diabetes, this isn't for you. And if you're already on a GLP-1 medication for diabetes, switching needs careful planning rather than overlap.

Why pharmacist-led care matters

The combination of regulated dispensing, in-person consultation, ongoing monitoring, and the ability to see the same clinician each visit makes community pharmacy a natural home for a structured weight management programme. The MHRA's requirement for wraparound care effectively codified what good services were already doing — and ruled out the prescription-only models that grew up over 2024.

If you're considering Mounjaro, the most useful next step is a 20–30 minute consultation: it's where eligibility gets confirmed, expectations get set, the right starting dose gets agreed, and you find out whether the programme fits how you actually live.